General
Correct hypocalcemia and other disturbances of bone and mineral metabolism prior to initiation of therapy.
Provide supplemental calcium and vitamin D if dietary intake is inadequate.
Administration
Oral Administration
Administer orally with a full glass (180–240 mL) of plain water ≥60 minutes prior to the first food, beverage (other than plain water), or other orally administered drug or supplement (including vitamins, antacids, and calcium) of the day.   (See Food under Pharmacokinetics.)
Avoid lying down for ≥60 minutes following administration.
Do not to suck or chew tablets; potential for oropharyngeal ulceration. (See Upper GI Effects under Cautions.)
If a morning daily oral dose is missed, do not take missed dose later that same day. Resume the regular schedule the next day.
When administered monthly, take tablets in the morning on the same day each month. If a monthly dose is missed and the next scheduled dose is more than 7 days away, take the missed dose the next morning after it is remembered and resume the regular schedule. If the next scheduled dose is 1–7 days away, maintain the regular schedule; do not take more than one 150-mg tablet within the same week.
IV Administration
Administer by IV injection once every 3 months by a health-care professional. 
Injection must only be administered IV.  Safety and efficacy of IV injection administered by other routes not established.
Because of the risk of anaphylaxis or other severe hypersensitivity reactions, appropriate medical support should be readily available during IV administration. (See Hypersensitivity under Cautions.)
If a dose is missed, reschedule administration with a health-care professional as soon as possible. Schedule subsequent injections at 3-month intervals; should not be administered more often than once every 3 months.
Administration Risks
Take care to avoid intra-arterial or paravenous injection as such administration could result in tissue damage.
Rate of Administration
Administer IV over a period of 15–30 seconds.
Dosage
Available as ibandronate sodium (as the monosodium monohydrate); dosage expressed in terms of ibandronate. 
Adults
Osteoporosis
Prevention in Postmenopausal Women
150 mg once monthly.
Osteoporosis
Treatment in Postmenopausal Women
150 mg once monthly.
Optimal duration of treatment not established. Safety and efficacy based on data over 3 years. Reevaluate need for continued therapy periodically in all patients receiving bisphosphonates. Consider discontinuance of bisphosphonate therapy after 3–5 years in patients at low risk of fracture. Evaluate fracture risk periodically in patients who discontinue therapy.
IV
3 mg once every 3 months.
Optimal duration of treatment not established. Safety and efficacy of IV ibandronate based on data supporting fracture reduction over 1 year of treatment. Reevaluate need for continued therapy periodically in all patients receiving bisphosphonates. Consider discontinuance of bisphosphonate therapy after 3–5 years in patients at low risk of fracture. Evaluate fracture risk periodically in patients who discontinue therapy.
Special Populations
Renal Impairment
Oral or IV
Dosage adjustments not necessary in patients with mild to moderate renal impairment (Clcr ≥30 mL/minute); use not recommended in patients with severe renal impairment (Clcr <30 mL/minute).   
 Detailed Ibandronate dosage information
